Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
- PMID: 22995653
- DOI: 10.1016/S1470-2045(12)70379-0
Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study
Erratum in
- Lancet Oncol. 2012 Nov;13(11):e464
- Lancet Oncol. 2014 Aug;15(9):e365
Abstract
Background: Abiraterone acetate improved overall survival in metastatic castration-resistant prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo-controlled phase 3 study. Here, we present the final analysis of the study before crossover from placebo to abiraterone acetate (after 775 of the prespecified 797 death events).
Methods: Between May 8, 2008, and July 28, 2009, this study enrolled 1195 patients at 147 sites in 13 countries. Patients were eligible if they had metastatic castration-resistant prostate cancer progressing after docetaxel. Patients were stratified according to baseline Eastern Cooperative Oncology Group (ECOG) performance status, worst pain over the past 24 h on the Brief Pain Inventory-Short Form, number of previous chemotherapy regimens, and type of progression. Patients were randomly assigned (ratio 2:1) to receive either abiraterone acetate (1000 mg, once daily and orally) plus prednisone (5 mg, orally twice daily) or placebo plus prednisone with a permuted block method via an interactive web response system. The primary endpoint was overall survival, analysed in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT00091442.
Findings: Of the 1195 eligible patients, 797 were randomly assigned to receive abiraterone acetate plus prednisone (abiraterone group) and 398 to receive placebo plus prednisone (placebo group). At median follow-up of 20·2 months (IQR 18·4-22·1), median overall survival for the abiraterone group was longer than in the placebo group (15·8 months [95% CI 14·8-17·0] vs 11·2 months [10·4-13·1]; hazard ratio [HR] 0·74, 95% CI 0·64-0·86; p<0·0001). Median time to PSA progression (8·5 months, 95% CI 8·3-11·1, in the abiraterone group vs 6·6 months, 5·6-8·3, in the placebo group; HR 0·63, 0·52-0·78; p<0·0001), median radiologic progression-free survival (5·6 months, 5·6-6·5, vs 3·6 months, 2·9-5·5; HR 0·66, 0·58-0·76; p<0·0001), and proportion of patients who had a PSA response (235 [29·5%] of 797 patients vs 22 [5·5%] of 398; p<0·0001) were all improved in the abiraterone group compared with the placebo group. The most common grade 3-4 adverse events were fatigue (72 [9%] of 791 patients in the abiraterone group vs 41 [10%] of 394 in the placebo group), anaemia (62 [8%] vs 32 [8%]), back pain (56 [7%] vs 40 [10%]), and bone pain (51 [6%] vs 31 [8%]).
Interpretation: This final analysis confirms that abiraterone acetate significantly prolongs overall survival in patients with metastatic castration-resistant prostate cancer who have progressed after docetaxel treatment. No new safety signals were identified with increased follow-up.
Trial registration: ClinicalTrials.gov NCT00638690.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Comment in
-
Abiraterone acetate for metastatic prostate cancer.Lancet Oncol. 2012 Oct;13(10):958-9. doi: 10.1016/S1470-2045(12)70392-3. Epub 2012 Sep 18. Lancet Oncol. 2012. PMID: 22995649 No abstract available.
Similar articles
-
Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.Lancet Oncol. 2015 Feb;16(2):152-60. doi: 10.1016/S1470-2045(14)71205-7. Epub 2015 Jan 16. Lancet Oncol. 2015. PMID: 25601341 Clinical Trial.
-
Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.Lancet Oncol. 2013 Nov;14(12):1193-9. doi: 10.1016/S1470-2045(13)70424-8. Epub 2013 Sep 25. Lancet Oncol. 2013. PMID: 24075621 Clinical Trial.
-
Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.Lancet Oncol. 2012 Dec;13(12):1210-7. doi: 10.1016/S1470-2045(12)70473-4. Epub 2012 Nov 9. Lancet Oncol. 2012. PMID: 23142059 Clinical Trial.
-
[Abiraterone acetate (AA): current guidelines of prescription of abiraterone].Bull Cancer. 2014 Apr;101(4):388-93. doi: 10.1684/bdc.2014.1932. Bull Cancer. 2014. PMID: 24793632 Review. French.
-
Abiraterone acetate: a review of its use in patients with metastatic castration-resistant prostate cancer.Drugs. 2013 Dec;73(18):2077-91. doi: 10.1007/s40265-013-0150-z. Drugs. 2013. PMID: 24271422 Review.
Cited by
-
Steroidogenic cytochrome P450 17A1 structure and function.Mol Cell Endocrinol. 2021 May 15;528:111261. doi: 10.1016/j.mce.2021.111261. Epub 2021 Mar 26. Mol Cell Endocrinol. 2021. PMID: 33781841 Free PMC article. Review.
-
Cost-effectiveness Analysis of Radium-223 Dichloride in Metastatic Castration-Resistant Prostate Cancer Patients Without Previous Chemotherapy Treatment in Spain.J Health Econ Outcomes Res. 2018 Jan 29;6(1):1-14. doi: 10.36469/9777. eCollection 2018. J Health Econ Outcomes Res. 2018. PMID: 32685568 Free PMC article.
-
An update on enzalutamide in the treatment of prostate cancer.Ther Adv Urol. 2015 Feb;7(1):9-21. doi: 10.1177/1756287214555336. Ther Adv Urol. 2015. PMID: 25642291 Free PMC article. Review.
-
Cost-Effectiveness Analysis of Systemic Therapy for Intensification of Treatment in Metastatic Hormone-Sensitive Prostate Cancer in India.Appl Health Econ Health Policy. 2024 May;22(3):415-426. doi: 10.1007/s40258-023-00866-w. Epub 2024 Jan 10. Appl Health Econ Health Policy. 2024. PMID: 38198103
-
Development, validation and application of a stable isotope dilution liquid chromatography electrospray ionization/selected reaction monitoring/mass spectrometry (SID-LC/ESI/SRM/MS) method for quantification of keto-androgens in human serum.J Steroid Biochem Mol Biol. 2013 Nov;138:281-9. doi: 10.1016/j.jsbmb.2013.06.014. Epub 2013 Jul 10. J Steroid Biochem Mol Biol. 2013. PMID: 23851165 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous